- Home
- RYN vs SRRK Comparison
RYN vs SRRK Comparison
Compare RYN & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYN
- SRRK
- Stock Information
- Founded
- RYN 1926
- SRRK 2012
- Country
- RYN United States
- SRRK United States
- Employees
- RYN N/A
- SRRK N/A
- Industry
- RYN Real Estate Investment Trusts
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RYN Real Estate
- SRRK Health Care
- Exchange
- RYN Nasdaq
- SRRK Nasdaq
- Market Cap
- RYN 3.5B
- SRRK 3.2B
- IPO Year
- RYN N/A
- SRRK 2018
- Fundamental
- Price
- RYN $23.57
- SRRK $40.72
- Analyst Decision
- RYN Hold
- SRRK Strong Buy
- Analyst Count
- RYN 4
- SRRK 7
- Target Price
- RYN $27.75
- SRRK $42.17
- AVG Volume (30 Days)
- RYN 1.3M
- SRRK 1.3M
- Earning Date
- RYN 08-06-2025
- SRRK 08-07-2025
- Dividend Yield
- RYN 12.27%
- SRRK N/A
- EPS Growth
- RYN 108.38
- SRRK N/A
- EPS
- RYN 2.33
- SRRK N/A
- Revenue
- RYN $1,233,027,000.00
- SRRK N/A
- Revenue This Year
- RYN N/A
- SRRK N/A
- Revenue Next Year
- RYN $3.99
- SRRK $1,960.31
- P/E Ratio
- RYN $10.09
- SRRK N/A
- Revenue Growth
- RYN 17.89
- SRRK N/A
- 52 Week Low
- RYN $21.84
- SRRK $6.76
- 52 Week High
- RYN $32.88
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- RYN 54.93
- SRRK 63.10
- Support Level
- RYN $23.09
- SRRK $36.91
- Resistance Level
- RYN $23.89
- SRRK $38.15
- Average True Range (ATR)
- RYN 0.48
- SRRK 1.95
- MACD
- RYN 0.11
- SRRK 0.52
- Stochastic Oscillator
- RYN 84.39
- SRRK 68.96
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. The firm also owns timberland in New Zealand. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.